AstraZeneca Plc - Company Profile
Powered by 
All the data and insights you need on AstraZeneca Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date AstraZeneca Plc Strategy Report
- Understand AstraZeneca Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
AstraZeneca Plc Catalyst Calendar
Proactively evaluate AstraZeneca Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of AstraZeneca Plc Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 Aug 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 30 Aug 2019 | Phase I/II Trial Initiation | AstraZeneca Plc | AZN | acalabrutinib maleate | Oncology | Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed Chronic Lymphocytic Leukemia (CLL); Unspecified B-Cell Lymphomas | Clinical Trial Registry |
| 27 Aug 2019 | Phase I Trial Completion | MedImmune LLC (Inactive) | - | cotadutide | Metabolic Disorders | Obesity | Clinical Trial Registry |
| 27 Aug 2019 | Phase II/III Trial Completion | AstraZeneca Plc; Merck & Co Inc; Myriad Genetics Inc; PPD Inc | AZN; MRK; MYGN | cediranib maleate; olaparib | Oncology | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer | Company Reports |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer